Literature DB >> 10353740

Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival.

S Kayastha1, A N Freedman, M S Piver, J Mukkamalla, M Romero-Guittierez, B A Werness.   

Abstract

Most ovarian carcinomas present at advanced stage, principally as the result of dissemination to peritoneal sites. Standard CD44 (CD44S) is the principal receptor for hyaluronic acid, and in vitro and animal studies have suggested that the attachment of ovarian carcinoma cells to the peritoneal mesothelium involves the interaction between CD44S on ovarian carcinoma cells and hyaluronic acid on mesothelial surfaces. We, therefore, analyzed a series of ovarian carcinomas for the expression of CD44S by immunohistochemistry to see whether expression of this receptor by tumor cells correlated with clinicopathological factors and measures of patient outcome. Fifty-six fixed, paraffin-embedded primary epithelial ovarian tumors were immunostained with antibody to CD44S. Membrane staining was considered positive, and results were correlated with stage, grade, age, histology, and survival. Twenty-two (39%) tumors were positive for CD44S. There was no correlation between CD44 expression and histological type, grade, age, or stage. However, CD44 expression was significantly associated with survival in both univariate (P = 0.003) and multivariate (P = 0.006) analyses. These results support a role for CD44S expression in the spread of ovarian epithelial cancer and suggest that expression of this molecule is a significant independent predictor of survival in women with this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353740

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Authors:  Michael A Gold; William E Brady; Heather A Lankes; Peter G Rose; Joseph L Kelley; Koen De Geest; Marta A Crispens; Kimberly E Resnick; Stephen B Howell
Journal:  Gynecol Oncol       Date:  2012-03-22       Impact factor: 5.482

2.  Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications.

Authors:  H S Berner; B Davidson; A Berner; B Risberg; G B Kristensen; C G Trope; G Van de Putte; J M Nesland
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.

Authors:  Eun Jung Cho; Bo Sun; Kyung-Oh Doh; Erin M Wilson; Sandra Torregrosa-Allen; Bennett D Elzey; Yoon Yeo
Journal:  Biomaterials       Date:  2014-10-24       Impact factor: 12.479

4.  Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer.

Authors:  Sophia A Shahin; Ruining Wang; Shirleen I Simargi; Altagracia Contreras; Liliana Parra Echavarria; Louise Qu; Wei Wen; Thanh Dellinger; Juli Unternaehrer; Fuyuhiko Tamanoi; Jeffrey I Zink; Carlotta A Glackin
Journal:  Nanomedicine       Date:  2018-04-14       Impact factor: 5.307

5.  Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation.

Authors:  Subarna A Khan; Amy C Cook; Maya Kappil; Ursula Günthert; Ann F Chambers; Alan B Tuck; David T Denhardt
Journal:  Clin Exp Metastasis       Date:  2006-05-12       Impact factor: 5.150

6.  Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.

Authors:  Sun Joo Lee; Sukhen C Ghosh; Hee Dong Han; Rebecca L Stone; Justin Bottsford-Miller; De Yue Shen; Edmond J Auzenne; Alejandro Lopez-Araujo; Chunhua Lu; Masato Nishimura; Chad V Pecot; Behrouz Zand; Duangmani Thanapprapasr; Nicholas B Jennings; Yu Kang; Jie Huang; Wei Hu; Jim Klostergaard; Anil K Sood
Journal:  Clin Cancer Res       Date:  2012-06-12       Impact factor: 12.531

7.  Development and validation of H11B2C2 monoclonal antibody-reactive hyaluronic acid binding protein: overexpression of HABP during human tumor progression.

Authors:  Rajeev K Boregowda; Hitesh N Appaiah; Mortha Karunakumar; Shivanna Parameshwariah; Geetha Avadani; Sunila Sunila; Shibdas Banerjee
Journal:  Tumour Biol       Date:  2012-10-26

8.  High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.

Authors:  Ming Liu; Gil Mor; Huan Cheng; Xue Xiang; Pei Hui; Thomas Rutherford; Gang Yin; David L Rimm; Jennie Holmberg; Ayesha Alvero; Dan-Arin Silasi
Journal:  Reprod Sci       Date:  2012-11-20       Impact factor: 3.060

9.  Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.

Authors:  Edmond Auzenne; Sukhen C Ghosh; Mojgan Khodadadian; Belinda Rivera; David Farquhar; Roger E Price; Murali Ravoori; Vikas Kundra; Ralph S Freedman; Jim Klostergaard
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

10.  Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.

Authors:  H Chen; J Hao; L Wang; Y Li
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.